The medical black technology system of the top student

Chapter 246 A new issue of Alzheimer’s disease

"In the Morris water maze test, the Alzheimer's disease mice in the control group had fewer activity trajectories in the water platform area, and it took longer to find the water platform."

"The experimental group of Alzheimer's mice treated with the drug significantly reduced the time it took to find the platform in the water."

"In behavioral tests, spatial cognition and memory abilities were restored in drug-treated Alzheimer's mice."

In the study room.

Lu Liang's fingers were tapping quickly on the keyboard, and he was quickly organizing various data into a paper.

After the animal test was completed, Tan Bin from the biological company had already sent the test data to Lu Liang. There were two sets of data in total.

One is the data from the animal behavior test, while the other is the data about the sample testing, including the results of tissue sections and immunofluorescence analysis.

The detection of the sample cannot be used as a direct result of the entire test, but it can play a certain indirect proving role.

"The mice were dissected to obtain brain tissue, the cerebral cortex and hippocampus were isolated, tissue paraffin sections were made, and immunohistochemical analysis was performed."

“The deposition of β-amyloid protein in the cerebral cortex of mice in the control group was obvious, indicating that they had relatively severe damage. However, in the experimental group of Alzheimer’s disease mice treated with drugs, the deposition of β-amyloid protein in the cerebral cortex was significantly improved. "

"In addition, immunofluorescence analysis was performed on the brain tissues of the two groups of mice, and C3 protein, GFAP protein and NeuN protein were immunostained respectively."

"It was found that the expression of C3 protein and GFAP in the brain tissue of mice in the control group was significantly increased, while NeuN protein was significantly reduced, indicating that neurons were lost."

"But in the experimental group of mice treated with the drug, the expression of C3 protein and GFAP was significantly reduced, and the level of NeuN protein was significantly increased, meaning that the distribution of mature neurons was increased."

"This shows that the drug improves nerves in mice with Alzheimer's disease."

After carefully revising it twice and confirming that there were no problems with the article, Lu Liang stretched hard.

Then he opened the system and glanced at the source points brought by this article.

[Source point +0.7]

The gold content of this article is not low, it belongs to the gold content of a top publication.

However, Lu Liang couldn't help but think about another question.

So where should this article be submitted?

To be honest, this kind of research in the neurological field is really not easy to submit.

After Lu Liang hesitated for a moment, he finally chose to submit his article to the journal "Alzheimer's disease", which specializes in research related to Alzheimer's disease.

Among the major journals in the field of neurological research, it is also considered the top journal.

Lu Liang didn't think much. He found the email address of the editorial department on the official website of the journal "Alzheimer's disease", and then adjusted the format of the article according to the template and requirements posted on the official website.

After doing all this, Lu Liang sent the article to the other party.

Soon, Lu Liang received an automatic reply from the other party's editorial department.

"Thank you for choosing this journal to submit your manuscript. We have received your manuscript, and the manuscript number is 2023030 (the manuscript number is used to check the progress of the manuscript, please record it)"

When he saw this email, Lu Liang knew that the article had been submitted, and he was just waiting for the other party's review results.

As soon as Lu Liang closed the mailbox, the door of the study room was pushed open.

Lu Liang turned around and saw that the person walking in was Wang Wentao. Lu Liang asked, "What do you mean, where is the teacher?"

Wang Wentao replied: "The data has been shown to the teacher, but the teacher said that the arrangement of clinical trials should take a while."

After getting the test results and confirming that the test was feasible, the first step was naturally to go to Ji Hong to arrange a clinical trial.

However, the arrangement of this clinical trial was really difficult for Ji Hong.

After all, Ji Hong's research focuses more on lung cancer, and most of the people he knows are related to lung cancer.

If it is a clinical trial of lung cancer drugs, Ji Hong can quickly find someone to arrange it.

However, in this neuro-related research field, Ji Hong has few connections, so it may be inconvenient to arrange clinical trials.

Lu Liang thought for a moment, then looked at Wang Wentao and asked, "How is your grandma doing?"

Wang Wentao hesitated for a moment and replied: "After the last checkup, the diagnosis has basically been confirmed. However, the doctor said that my grandma is still in the early stages and can be treated with cholinesterase inhibitors or NMDA receptor antagonists. medical treatement."

"It can delay the onset of Alzheimer's disease a little bit, so you don't have to worry about Alzheimer's disease getting worse quickly for the time being."

After listening to Wang Wentao's words, Lu Liang hesitated for two seconds and then made his decision immediately.

He took out his cell phone and quickly dialed Chen Shen's number.

Zhou Jun was bored and browsing the latest issues of the major journals in the neurological field.

After not finding what he wanted to see, Zhou Jun closed the page on the computer and couldn't help but sigh.

"How long has it been? Why is there no movement at all?"

Ever since Lu Liang's review on Alzheimer's disease was published and attracted attention on the Internet, Zhou Jun has been paying attention to the latest research progress on Alzheimer's disease in various journals.

According to Zhou Jun's expectation, in the next period of time, Lu Liang's experiments should continue to make new breakthroughs, and then new research results will continue to be published.

But the facts did not develop as Zhou Jun expected.

After squatting for so long, Zhou Jun didn't even hear any news, let alone the latest research results being published.

Zhou Jun couldn't help but feel a little disappointed. He originally wanted to take this opportunity to make a video recording.

At the same time, this also made Zhou Jun feel a little suspicious.

Could it be that Lu Liang's review of "Research Progress of Antibodies Targeting Different Targets of Amyloid" was really written casually, and that the other party had no intention of developing targeted drugs for Alzheimer's disease at all?

Or is Alzheimer's disease really a disease that is impossible to defeat, and there has been no progress in Lu Liang's experiments?

Faced with the current situation, Zhou Jun could only make random guesses.

Just as Zhou Jun was thinking about these things, the sound of an email notification interrupted Zhou Jun's thoughts. Zhou Jun glanced at it and saw that it was an email sent to him by the journal he followed.

"Dear Dr. Zhou, the following is a new issue of the journal article "Alzheimer's disease". I would like to inform you. I hope it will be helpful to you."

Zhou Jun sighed, but he still opened the table of contents of the new issue of the journal with little interest.

However, the next second, Zhou Jun was stunned for a moment.

Then he sat up straight suddenly, and his breathing became even more rapid.

After waiting for so long, he finally saw what he wanted to see.

In the latest issue of the journal "Alzheimer's disease\

,"The author of the first article is none other than Lu Liang.

My tutor is on a business trip and no one cares about me. I just made a small fortune and made a code of two thousand, hehe.